source
- Vistagen’s anxiety nasal spray fails to outperform placebo in Phase 2 studyVistagen reported results of its Phase 2 trial of the investigational nasal spray fasedienol for social anxiety disorder. The study enrolled 61 patients who were randomly assigned to receive a sin…
- Replimune’s Tudriqev immunotherapy receives FDA accelerated approval for advanced melanomaReplimune announced that the FDA granted accelerated approval for its immunotherapy, now branded Tudriqev, in combination with Bristol Myers Squibb’s Opdivo. The decision follows two earlier reject…